Compare ResMed Inc. (RMD) vs SoFi Technologies Inc (SOFI) Price & Performance

ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.

The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.

SoFi Technologies trades at $18.01, down 1.15% amid mixed signals. The stock shows strong fundamental progress with 40% revenue growth and three consecutive earnings beats, though Q3 2026 expectations of $0.17 EPS present a high bar. Technical indicators are neutral with support at $18 and resistance at $19. Recent partnership with Payward expands banking infrastructure capabilities while rising Treasury yields pressure fintech lenders.

SoFi presents a growth story with expanding profitability and strategic partnerships, though negative operating cash flow and high valuation multiples warrant caution. Analyst consensus targets $20.78 with 37% buy ratings, suggesting moderate upside potential balanced against macroeconomic sensitivity and competitive pressures in the digital banking space.